Home>Topics>Funds>Morgan Stanley Ins Muni Secs

Morgan Stanley Ins Muni Secs XIMSX

  1. All
  2. Commentary
  3. Headlines
    1. Belviq Sales Benefit From Advertising - Up 2.8%

      Headlines

      Fri, 26 Sep 2014

      Pharmaceuticals (NASDAQ: ARNA ) saw a nice week over week gain on the heels of a more robust advertising campaign. According to IMS Health, script sales this week were about 11,900 which represents a gain of 2.8% over last weeks numbers. While a 2.8

    2. IG Labs acquires drug portfolio from AstraZeneca

      Headlines

      Thu, 25 Sep 2014

      All had been cleared by the FDA via ANDAs or NDAs prior to their discontinuation or withdrawal from the market. According to IMS Health, the U.S. addressable market for the products is ~$200M. Almost half of the 18 drugs are on the FDA shortage list

    3. IMS Has Deleveraged While Growing Revenues And Executing Accretive Acquisitions

      Headlines

      Thu, 25 Sep 2014

      By Dallas Salazar : Five months ago when IMS Health Holdings, Inc. (NYSE: IMS ) held its IPO I opined that the company should be purchased in Core Position quantity. Now, for my former clients on the retail side that would mean anywhere from

    4. Dr. Reddy's launches generic Xopenex in U.S.

      Headlines

      Wed, 24 Sep 2014

      mg/3 mL unit dose vials in the U.S. The product is a generic version of Sunovion Pharmaceuticals' Xopenex (levalbuterol hydrochloride) inhalation solution. According to IMS Health, the U.S. market is ~$270M. Post your comment!

    5. Lannett begins shipping oxycodone solution

      Headlines

      Mon, 22 Sep 2014

      Lannett Company (NYSE: LCI ) commences shipping its recently-approved oxycodone hydrochloride oral solution USP, 100 mg/5 mL. The U.S. wholesale market is ~43M per IMS Health. The company reaffirms its fiscal 2015 guidance. Post your comment!

    6. Belviq Sales See Holiday Dip - Still On Track

      Headlines

      Fri, 12 Sep 2014

      anticipated dip this week due to the Labor Day holiday. Sales were down 12% from last week's numbers according to industry source IMS Health. While seeing sales dip is never a positive, the news was essentially expected and the stock price did not carry an overwhelming

    7. Strong Portfolio Will Drive Growth For Mylan

      Headlines

      Thu, 11 Sep 2014

      range of antiretroviral therapies upon which around 40% of HIV/AIDS patients in developing countries depend. According to IMS Health , Mylan currently has 294 abbreviated new drug applications pending for FDA approval which represent $105.7 billion in

    8. Orexigen's Contrave Approved: What It Means To Arena

      Headlines

      Thu, 11 Sep 2014

      By Spencer Osborne : Orexigen (NASDAQ: OREX ) received FDA approval for its anti-obesity drug Contrave on September 10, 2014. This is now the third "new" entrant into the space. Belviq, from Arena Pharmaceuticals (NASDAQ: ARNA ) and Qsymia from Vivus (NASDAQ: VVUS ) have already been on the market

    9. FDA clears Lannett's generic oxycodone solution

      Headlines

      Wed, 10 Sep 2014

      mg/5 mL. The product is the therapeutic equivalent of Lehigh Valley Technologies' Oxycodone Hydrochloride Oral Solution USP, 100 mg/5 mL. According the IMS Health, the U.S. wholesale market is ~$43M per year. Post your comment!

    10. Mylan secures U.S. rights to DVT drug

      Headlines

      Wed, 10 Sep 2014

      in escrow pending the satisfaction of certain conditions. Aspen will supply Arixtra and its generic to Mylan. According to IMS Health, U.S. sales of branded Arixtra were $18.8M for the 12-month period ending June 30, 2014. Generic Arixtra sales

    « Prev12345Next »
    Content Partners